Anti-HIV Activity and Resistance Profile of the CXC Chemokine Receptor 4 Antagonist POL3026
暂无分享,去创建一个
Eduardo Pauls | Mercedes Armand-Ugón | Imma Clotet-Codina | Bonaventura Clotet | B. Clotet | F. Gombert | E. Ballana | E. Pauls | J. Esté | A. Llano | G. Moncunill | Gemma Moncunill | Anuska Llano | B. Romagnoli | J. W. Vrijbloed | Ester Ballana | Mercedes Armand-Ugón | I. Clotet-Codina | Steve De Marco | Barbara Romagnoli | José A Esté | Jan W Vrijbloed | Frank O Gombert | Steve De Marco
[1] E. De Clercq,et al. Shift of Clinical Human Immunodeficiency Virus Type 1 Isolates from X4 to R5 and Prevention of Emergence of the Syncytium-Inducing Phenotype by Blockade of CXCR4 , 1999, Journal of Virology.
[2] E. De Clercq,et al. Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir). , 1998, Molecular pharmacology.
[3] L. Menéndez-Arias,et al. HIV-resistance to viral entry inhibitors. , 2004, Current pharmaceutical design.
[4] R. Doms. Chemokine receptors and HIV entry. , 2001, AIDS.
[5] E. De Clercq,et al. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future. , 2004, Chemistry & biodiversity.
[6] B Clotet,et al. Activity of different bicyclam derivatives against human immunodeficiency virus depends on their interaction with the CXCR4 chemokine receptor. , 1999, Molecular pharmacology.
[7] J. Barretina,et al. Reduced Fitness of HIV-1 Resistant to Cxcr4 Antagonists , 2003, Antiviral therapy.
[8] E. De Clercq,et al. T-Cell-Line-Tropic Human Immunodeficiency Virus Type 1 That Is Made Resistant to Stromal Cell-Derived Factor 1α Contains Mutations in the Envelope gp120 but Does Not Show a Switch in Coreceptor Use , 1998, Journal of Virology.
[9] B. Clotet,et al. HIV-1 resistance to the gp41-dependent fusion inhibitor C-34. , 2003, Antiviral research.
[10] B. Korber,et al. A new classification for HIV-1 , 1998, Nature.
[11] B. Clotet,et al. The anti-HIV activity of ADS-J1 targets the HIV-1 gp120. , 2005, Virology.
[12] I. Keet,et al. Prognostic Value of HIV-1 Syncytium-Inducing Phenotype for Rate of CD4+ Cell Depletion and Progression to AIDS , 1993, Annals of Internal Medicine.
[13] J. Park,et al. Multiple-Dose Escalation Study of the Safety, Pharmacokinetics, and Biologic Activity of Oral AMD070, a Selective CXCR4 Receptor Inhibitor, in Human Subjects , 2007, Antimicrobial Agents and Chemotherapy.
[14] N. Yoshida,et al. A Small Molecule CXCR4 Inhibitor that Blocks T Cell Line–tropic HIV-1 Infection , 1997, The Journal of experimental medicine.
[15] R. Doms,et al. A Small-molecule Inhibitor Directed against the Chemokine Receptor CXCR4 Prevents its Use as an HIV-1 Coreceptor , 1997, The Journal of experimental medicine.
[16] B. Clotet,et al. Evaluation of the anti-HIV activity of statins , 2005, AIDS.
[17] Ronald G. Collman,et al. Preferential Use of CXCR4 by R5X4 Human Immunodeficiency Virus Type 1 Isolates for Infection of Primary Lymphocytes , 2005, Journal of Virology.
[18] John A. Robinson,et al. Discovery of novel, highly potent and selective beta-hairpin mimetic CXCR4 inhibitors with excellent anti-HIV activity and pharmacokinetic profiles. , 2006, Bioorganic & medicinal chemistry.
[19] B. Clotet,et al. HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro , 2008, AIDS.
[20] E. De Clercq,et al. The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication , 1996, Journal of virology.
[21] J. Esté,et al. Virus entry as a target for anti-HIV intervention. , 2003, Current medicinal chemistry.
[22] B. Clotet,et al. Induction of interleukins IL‐6 and IL‐8 by siRNA , 2006, Clinical and experimental immunology.
[23] A. Sylwester,et al. Evidence for the HIV-1 phenotype switch as a causal factor in acquired immunodeficiency , 1998, Nature Medicine.
[24] F. Mitjans,et al. Inhibition of human immunodeficiency virus type 1 infection in macrophages by an alpha-v integrin blocking antibody. , 2006, Antiviral research.
[25] M. Lederman,et al. Biology of CCR5 and its role in HIV infection and treatment. , 2006, JAMA.
[26] J. Grivel,et al. CCR5- and CXCR4-tropic HIV-1 are equally cytopathic for their T-cell targets in human lymphoid tissue , 1999, Nature Medicine.
[27] Amalio Telenti,et al. HIV entry inhibitors , 2007, The Lancet.
[28] Helen Piontkivska,et al. HIV type 1 tropism and inhibitors of viral entry: clinical implications. , 2006, AIDS reviews.
[29] P. Harrigan,et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. , 2005, The Journal of infectious diseases.
[30] Mike Youle,et al. Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 Antagonist Maraviroc Is from a Pretreatment CXCR4-Using Virus Reservoir , 2006, Journal of Virology.
[31] B. Gazzard,et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. , 2005, The Journal of infectious diseases.
[32] E. Clercq. The bicyclam AMD3100 story , 2003, Nature Reviews Drug Discovery.
[33] N. Graham,et al. HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response. , 2006, The Journal of infectious diseases.
[34] B. Clotet,et al. Multiparametric Assay To Screen and Dissect the Mode of Action of Anti-Human Immunodeficiency Virus Envelope Drugs , 2005, Antimicrobial Agents and Chemotherapy.
[35] E. De Clercq,et al. Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists. , 2000, Molecular pharmacology.
[36] S. Sato,et al. Biological and genetic characterization of a human immunodeficiency virus strain resistant to CXCR4 antagonist T134. , 2001, AIDS research and human retroviruses.
[37] Stephen C. Peiper,et al. Identification of a major co-receptor for primary isolates of HIV-1 , 1996, Nature.